Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function.

This antiserum specifically detects alpha synuclein.
Application Information:
IHC, WB, ELISA. Recommended to be used at a concentration of 1 µg/ml for immunohistochemistry (Paraffin sections); 0.5 µg/ml for WB and immunoblot. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.

Type: Primary
Antigen: alpha synuclein
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope: aa: 116-131
Host: Sheep
Isotype: IgG
Reactivity: Rat, Human, Mouse